|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eyre H, Kahn R and Robertson RM;
ACS/ADA/AHA Collaborative Writing Committee, : Preventing cancer,
cardiovascular disease, and diabetes: A common agenda for the
American cancer society, the American diabetes association, and the
American heart association. CA Cancer J Clin. 54:190–207. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brunelli A, Kim AW, Berger KI and
Addrizzo-Harris DJ: Physiologic evaluation of the patient with lung
cancer being considered for resectional surgery: Diagnosis and
management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 143
(Suppl 5):e166S–e190S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JL, Kim JE, Ahn JH, Lee DH, Lee J, Kim
CS, Hong JH, Hong B, Song C and Ahn H: Efficacy and safety of
docetaxel plus prednisolone chemotherapy for metastatic
hormone-refractory prostate adenocarcinoma: Single institutional
study in Korea. Cancer Res Treat. 42:12–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montero A, Fossella F, Hortobagyi G and
Valero V: Docetaxel for treatment of solid tumours: A systematic
review of clinical data. Lancet Oncol. 6:229–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pritchard AL and Hayward NK: Molecular
pathways: Mitogen-activated protein kinase pathway mutations and
drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohammadian J, Sabzichi M, Molavi O,
Shanehbandi D and Samadi N: Combined treatment with stattic and
docetaxel alters the Bax/Bcl-2 gene expression ratio in human
prostate cancer cells. Asian Pac J Cancer Prev. 17:5031–5035.
2016.PubMed/NCBI
|
|
10
|
Yoo NJ, Kim MS and Park SW: Expression
analysis of caspase-6, caspase-9 and BNIP3 in prostate cancer.
Tumori. 96:138–142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winter RN, Kramer A, Borkowski A and
Kyprianou N: Loss of caspase-1 and caspase-3 protein expression in
human prostate cancer. Cancer Res. 61:1227–1232. 2001.PubMed/NCBI
|
|
12
|
Webber MM, Bello D and Quader S:
Immortalized and tumorigenic adult human prostatic epithelial cell
lines: Characteristics and applications Part 2. Tumorigenic cell
lines. Prostate. 30:58–64. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basch EM, Somerfield MR, Beer TM, Carducci
MA, Higano CS, Hussain MH and Scher HI; American Society of
Clinical Oncology, : American Society of Clinical Oncology
endorsement of the cancer care ontario practice guideline on
nonhormonal therapy for men with metastatic hormone-refractory
(castration-resistant) prostate cancer. J Clin Oncol. 25:5313–5318.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hughes C, Murphy A, Martin C, Sheils O and
O'Leary J: Molecular pathology of prostate cancer. J Clin Pathol.
58:673–684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Muenchen HJ, Poncza PJ and Pienta KJ:
Different docetaxel-induced apoptotic pathways are present in
prostate cancer cell lines LNCaP and PC-3. Urology. 57:366–370.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwang C: Overcoming docetaxel resistance
in prostate cancer: A perspective review. Ther Adv Med Oncol.
4:329–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morse DL, Gray H, Payne CM and Gillies RJ:
Docetaxel induces cell death through mitotic catastrophe in human
breast cancer cells. Mol Cancer Ther. 4:1495–1504. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fabbri F, Amadori D, Carloni S,
Brigliadori G, Tesei A, Ulivi P, Rosetti M, Vannini I, Arienti C,
Zoli W and Silvestrini R: Mitotic catastrophe and apoptosis induced
by docetaxel in hormone-refractory prostate cancer cells. J Cell
Physiol. 217:494–501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fabbri F, Carloni S, Brigliadori G, Zoli
W, Lapalombella R and Marini M: Sequential events of apoptosis
involving docetaxel, a microtubule-interfering agent: A cytometric
study. BMC Cell Biol. 7:62006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kahn B, Collazo J and Kyprianou N:
Androgen receptor as a driver of therapeutic resistance in advanced
prostate cancer. Int J Biol Sci. 10:588–595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Attar RM, Takimoto CH and Gottardis MM:
Castration-resistant prostate cancer: Locking up the molecular
escape routes. Clin Cancer Res. 15:3251–3255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gravis G, Fizazi K, Joly F, Oudard S,
Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B,
et al: Androgen-deprivation therapy alone or with docetaxel in
non-castrate metastatic prostate cancer (GETUG-AFU 15): A
randomised, open-label, phase 3 trial. Lancet Oncol. 14:149–158.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Loriot Y and Fizazi K: Taxanes: Still a
major weapon in the armamentarium against prostate cancer. Eur
Urol. 63:983–985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Akinleye A, Avvaru P, Furqan M, Song Y and
Liu D: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer
therapeutics. J Hematol Oncol. 6:882013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: Inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin HK, Yeh S, Kang HY and Chang C: Akt
suppresses androgen-induced apoptosis by phosphorylating and
inhibiting androgen receptor. Proc Natl Acad Sci USA. 98:7200–7205.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas C, Lamoureux F, Crafter C, Davies
BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME and Zoubeidi A:
Synergistic targeting of PI3K/AKT pathway and androgen receptor
axis significantly delays castration-resistant prostate cancer
progression in vivo. Mol Cancer Ther. 12:2342–2355. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Komura K, Jeong SH, Hinohara K, Qu F, Wang
X, Hiraki M, Azuma H, Lee GS, Kantoff PW and Sweeney CJ: Resistance
to docetaxel in prostate cancer is associated with androgen
receptor activation and loss of KDM5D expression. Proc Natl Acad
Sci USA. 113:6259–6264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Souza AG, Silva IBB, Campos-Fernandez E,
Barcelos LS, Souza JB, Marangoni K, Goulart LR and Alonso-Goulart
V: Comparative assay of 2D and 3D cell culture models:
Proliferation, gene expression and anticancer drug response. Curr
Pharm Des. 24:1689–1694. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
James ND and Mason M: Docetaxel and/or
zoledronic acid for hormone-naïve prostate cancer: First survival
results from STAMPEDE. J Clin Oncol. 33:50012015. View Article : Google Scholar
|
|
32
|
Singh SK, Banerjee S, Acosta EP, Lillard
JW and Singh R: Resveratrol induces cell cycle arrest and apoptosis
with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and
p27KIP1 pathway. Oncotarget. 8:17216–17228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui D, Dai J, Keller JM, Mizokami A, Xia S
and Keller ET: Notch pathway inhibition using PF-03084014, a
γ-secretase inhibitor (GSI), enhances the antitumor effect of
docetaxel in prostate cancer. Clin Cancer Res. 21:4619–4629. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu JD, Odman A, Higgins LM, Haugk K,
Vessella R, Ludwig DL and Plymate SR: In vivo effects of the human
type I insulin-like growth factor receptor antibody A12 on
androgen-dependent and androgen-independent xenograft human
prostate tumors. Clin Cancer Res. 11:3065–3074. 2005. View Article : Google Scholar : PubMed/NCBI
|
